Navigation Links
Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
Date:9/4/2007

- Clinical benefit observed in over 60% of evaluable patients -

SEOUL, South Korea, Sept. 4 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) today reported interim data from an ongoing phase 2 trial evaluating XL647 as first-line therapy for patients with non-small cell lung cancer (NSCLC). This open-label phase 2 trial is ongoing in previously untreated patients with stage IIIB or IV NSCLC who have adenocarcinoma histology and meet one of the following three criteria: Asian descent, female gender, or no or minimal smoking history. XL647 is administered orally, at a dose of 350 mg on Days 1-5 of repeated 14-day cycles.

To date, over 60% of evaluable patients in the phase 2 study have had partial responses (PR) or stable disease (SD) as their best response. Importantly, responses have been observed in patients with and without activating mutations in the epidermal growth factor receptor (EGFR), a target of XL647. Activating mutations in EGFR have been associated with improved sensitivity to other EGFR inhibitors. Dr. Shirish Gadgeel of Karmanos Cancer Institute at Wayne State University presented the data today in a poster (Abstract P3-136) at the 12th International Association for the Study of Lung Cancer World Conference on Lung Cancer, which is being held in Seoul, South Korea.

Key data points reported by Investigators:

-- XL647 has demonstrated anti-tumor activity in patients with previously

untreated NSCLC: >60% of evaluable patients experienced clinical

benefit as their best response (8 PR and 11 SD out of 30 evaluable

patients).

-- Of the 8 patients who experienced partial responses, 4 had EGFR exon 19

deletions, 1 had an EGFR L858R mu
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... For the first time, chemists have succeeded in measuring ... time resolution. The study reveals how vibration of a ... groups. , The study was performed at the ... from the University of Jyvskyl works as a visiting ... in the study. The second team was lead by ...
(Date:8/20/2014)... California (PRWEB) August 20, 2014 ... develop and apply the most complete climate and ... and demanding climate change issues. , Eight national ... forces with the National Center for Atmospheric Research, ... the new effort. Other participating national laboratories include ...
(Date:8/20/2014)... 2014  PAREXEL International Corporation (NASDAQ: PRXL ... the Baird Healthcare Conference in New York.  Ingo ... will be making a presentation on PAREXEL and discussing ... 3, 2014. A live webcast of the ... PAREXEL,s website at www.PAREXEL.com in the Upcoming ...
(Date:8/20/2014)... Not long ago, it was more ... performed late in the development cycle – even after ... trends suggest that, like many things GxP, expectations for ... years, multiple drug sponsors have been required by authorities ... during phase I/II. It’s not only clinical trial material ...
Breaking Biology Technology:Seeing a molecule breathe 2New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3PAREXEL International To Present At Baird Healthcare Conference 2Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2
... Va., Feb. 21, 2012 This year, approximately 7 million ... the female goes through a battery of tests, is to ... only 20% of men in couples struggling to conceive have ... Fertility ( www.spermcheck.com ), the only FDA approved at-home ...
... /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR ... manufacturing, and marketing of branded generic and proprietary pharmaceuticals ... unaudited financial results for the fourth quarter and fiscal ... 2012, before the market opens in the United States. ...
... 2012 ValGenesis, Inc., a world-class provider of ... its innovative ValGenesis Suite 2.5 has achieved SAP ... platform. Attaining this certified integration status deepens ValGenesis, ... The SAP Integration and Certification Center (SAP ...
Cached Biology Technology:SpermCheck® Fertility, the Only FDA Approved At-Home Screening Test for Men to Determine Normal or Low Sperm Count, Now Available to Couples Planning or Struggling to Conceive 2Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2011 Financial Results on Wednesday, March 7, 2012 2ValGenesis Suite 2.5 Certified by SAP as Powered by SAP NetWeaver® 2ValGenesis Suite 2.5 Certified by SAP as Powered by SAP NetWeaver® 3
(Date:8/21/2014)... Nine researchers from Beth Israel Deaconess Medical Center (BIDMC ... World,s Most Influential Scientific Minds 2014," a comprehensive ... a web resource for science metrics and research performance ... the most influential "are performing and publishing work that ... their science," according to a Thomson Reuters statement. Researchers ...
(Date:8/21/2014)... heard of the water window? It consists of radiations ... not absorbed by the water in biological tissues. New ... coherent radiations within the water window. These could be ... high-contrast image of the biological samples or to be ... identifies the physical mechanism needed to efficiently generate the ...
(Date:8/21/2014)... feeding tube connectors, designed by an international standards process, ... , According to an invited review published in the ... ( NCP ), the official journal of the American ... connectors will greatly reduce the occurrence of misconnection that ... Small-bore connectors, which are used to join medical devices, ...
Breaking Biology News(10 mins):BIDMC researchers named among 'the most influential scientific minds' 2BIDMC researchers named among 'the most influential scientific minds' 3Water window imaging opportunity 2New feeding tube connectors will improve patient safety 2
... WI, NOVEMBER 17, 2008 Global land use patterns ... urban stormwater management. Traditional stormwater management focuses on ... generally does little to restore the hydrologic cycle ... with low permeability. The lack of infiltration opportunities ...
... Mellon University,s Robotics Institute have received a total of ... Agriculture (USDA) to build automated farming systems. One is ... but both are designed to improve fruit quality and ... autonomous robotic vehicles or at fixed sites within the ...
... team of researchers led by investigators at the Albert ... that certain commonly-prescribed medications may have the unintended consequence ... finding could alter the way doctors prescribe migraine medicines. ... Headache , the Einstein-led study of more than ...
Cached Biology News:Urban trees enhance water infiltration 2Carnegie Mellon developing automated systems to enable precision farming of apples, oranges 2Carnegie Mellon developing automated systems to enable precision farming of apples, oranges 3Overuse of narcotics and barbiturates may make migraine worse 2
...
... is essential for hunting and analyzing ... such as EST sequencing projects, microarrays, ... kit is developed for normalization of ... intended for directional cloning. While most ...
Peptide-affinity Purified Polyclonal Antibody to ICEBERG Peptide with sequence EEDPQLASKMGLH, from C Terminus of the protein sequence according to NP_067546...
Purified anti-Fanconi anemia D2-Phosphorylated (Ser222)...
Biology Products: